Gilead investors spooked by UnitedHealthcare push to cut HIV drug costs
admin 1st November 2018 Uncategorised 0UnitedHealthcare unveiled a new program to reward patients for choosing cheaper HIV treatment options, scaring Gilead Sciences investors days later. Why so skittish? With Gilead’s hepatitis C meds in steep decline, its HIV franchise is carrying great expectations.
More: Gilead investors spooked by UnitedHealthcare push to cut HIV drug costs
Source: fierce